Special JLM issue "Information and Communication Technologies in Laboratory Medicine"

I have been asked to design a special issue of the Journal of Laboratory Medicine about "Information and Communication Technologies in Laboratory Medicine" together with Prof. Thomas Ganslandt (Mannheim).  This issue has been published and is now freely available here. I would like to thank all contributers and and members of De Gruyter publisher for making this special issue possible.

NPU, LOINC, and SNOMED CT: a comparison of terminologies for laboratory results reveals individual advantages and a lack of possibilities to encode interpretive comments

Background

Terminologies facilitate data exchange and enable laboratories to assist in patient care even if complex treatment pathways involve multiple stakeholders. This paper examines the three common terminologies Nomenclature for Properties and Units (NPU), Logical Observation Identifiers Names and Codes (LOINC), and SNOMED Clinical Terms (SNOMED CT).

Learning Health Systems and Laboratory Medicine

Health systems worldwide struggle to provide the optimal treatment amid the rapid pace of scientific progress and frequent structural changes. Learning health systems (LHS) that continuously analyze their data to generate evidence and to enable informed decisions have been proposed as a possible solution. This paper investigates the involvement of laboratory medicine in LHS and evaluates relevant systems according to their scope, enabling technologies, architecture for evidence generation, data-action latency, and social aspects. While laboratory medicine provides a central source of information in many large-scale LHS, there are also systems with a particular focus on laboratories. For example, external quality assessments are performed by sending samples with known quantities to laboratories worldwide to verify their analytical methods. This data are also analyzed for other purposes, such as post-market surveillance of devices. These schemes have operated successfully over several decades. Newer, innovative tools harvest the possibilities of wearable devices and increased connectivity. LHS in laboratory medicine need to be recognized and incorporated into systems of systems to generate better evidence. Further research on the roles of other stakeholders will identify opportunities and obstacles for building and maintaining successful LHS.

AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide

Background
Androgen receptor splice variant 7 (AR-V7) expression in circulating tumor cells
(CTCs) was demonstrated to predict poor treatment response in metastatic castrationresistant
prostate cancer (mCRPC) patients treated with abiraterone or enzalutamide.
Objective
To develop a practical and robust liquid profiling approach for direct quantification of
AR-V7 in peripheral whole blood without the need of CTC capturing and to determine
its potential to predict treatment response in mCRPC patients.

Fremdes POCT in sicheren Händen?

In der neue Medizinprodukte-Betreiberverordnung (MPBetreibV) wird klarer definiert, wer für die Anwendung eines Point-of-Care Tests (POCT) verantwortlich ist. Ausschlaggebend ist nicht, wem das Gerät gehört, sondern wer es tatsächlich benutzt. Dadurch können sich für eine Gesundheitseinrichtung weitreichende Konsequenzen ergeben.

Sicheres POCT durch kompetente Anwender

In den letzten Jahren wurde die analytische Qualität vieler Point-of-Care Tests kontinuierlich verbessert. Mittlerweile sind diese patientennahen Tests aus dem diagnostischen Leistungsspektrum vieler Labore nicht mehr wegzudenken. Aber eine gute Analytik alleine reicht nicht aus. Während in einem Zentrallabor eine geringe Anzahl gut ausgebildetes Fachpersonal sich mit der Durchführung klinisch-chemischer Analysen beschäftigt, werden Point-of-Care Tests von vielen, sehr heterogenen Anwendern durchgeführt.

Clinically relevant lot-to-lot reagent difference in a commercial immunoturbidimetric assay for glycated hemoglobin A1c

Objectives: Hemoglobin A1c (HbA1c) is employed for diagnosis and therapy monitoring of diabetes mellitus. The effect of a change of reagent lot on the measured values of a commercial immunoturbidimetric HbA1c assay (A1C3) was investigated.

Subscribe to